Wilshire Oncology Medical Group, Inc.
Oncology
Dr. Linda D. Bosserman, MD
Linda Bosserman practices Oncology. She researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine She over the years received 5 awards: "Top Doctors:LA Area", "Top Doctors:San Diego Area", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Southern California" and "Top MD". Linda D. Bosserman is a published doctor and has 27 publications published. The lastest was: 'Non-invasive measurements of bone mass in adult renal osteodystrophy.' Linda D. Bosserman, MD is registered with Medicare and accepts Medicare payments.
Publications
- Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase...
- Reply to I.A. Voutsadakis et al and A. Goyal et al.
- Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
- Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
- The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care.
- A copay foundation assistance support program for patients receiving intravenous cancer therapy.
- Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST stu...
- A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
- A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
- American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
- Non-invasive measurements of bone mass in adult renal osteodystrophy.
- Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma.
- Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia.
- Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
- Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
- Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients.
- If at first you don't succeed, don't quit, try again: The Centers For Medicare and Medicaid Services demonstration project on quality of care--2005 and 2006.
- Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
- Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
- Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.
- Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
- Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a rando...
- Implementing EHRs in community oncology practices.
- Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole.
- Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival.
- Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects wi...
Doctors Specialties
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:San Diego Area
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Southern California
- Top MD
Education
-
Stanford University
-
Stanford University School of Medicine
Hospital
-
Pomona Valley Hospital Medical Center
Drug Facts
| NPI NUMBER |
|
1346289824 |
| NPPES Provider LastName |
|
BOSSERMAN |
| NPPES Provider FirstName |
|
LINDA |
| NPPES Provider ZIPCode |
|
917303137 |
| NPPES Provider State |
|
CA |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
1166.0 |
| Distinct Opioid Count |
|
3.0 |
| Opioid Claim Count |
|
73.0 |
| Percent Opioid Claims |
|
6.26 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1346289824 |
| Last Name Of The Provider |
BOSSERMAN |
| First Name Of The Provider |
LINDA |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
